ArticleJournal of clinical medicine2025

New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers.

Giulia Battaglia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.